Overview
- UNAIDS said Friday that 38% fewer people received HIV prevention drug PrEP in 2025 across 62 countries, a fall from 3.3 million to 2.1 million users.
- The agency reported major drops in diagnosis tools, with HIV testing down about 22% in high-burden countries and condom funding falling by more than 90% in some places.
- Non-government groups including CHAI and EGPAF found declines in child diagnosis and care, with paediatric enrolment and early infant testing falling and no clear rebound since 2025 aid disruptions.
- Despite prevention losses, the number of people on antiretroviral treatment rose modestly to about 32.1 million by December 2025, yet slower gains and broken supply chains now threaten new drug rollouts such as lenacapavir.
- Experts link the disruption to abrupt cuts and policy changes in international aid, particularly US programme shifts that removed funding, contracts and community outreach, and the UN has called for renewed global solidarity ahead of a June political meeting on HIV.